Form 4: MEDIFAST Director Xian Ming Acquires Over 17,000 Restricted Stock Units as Compensation

MEDIFAST, Inc. Director Xian Ming acquired a total of 17,181 restricted stock units as part of annual director fees and compensation, with vesting scheduled for June 25, 2026.

Summary

• MEDIFAST, Inc. Director Xian Ming acquired 11,167.65 Restricted Stock Units (RSUs) on June 25, 2025, as part of annual director fees under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated (the "Plan").
• These 11,167.65 RSUs were granted from the Issuer's Amended and Restated 2012 Share Incentive Plan and will vest in full on June 25, 2026.
• An additional 6,013.35 Restricted Stock Units (RSUs) were acquired on June 25, 2025, as the reporting person elected to receive shares in lieu of cash compensation for annual service as a non-employee director, pursuant to the Plan.
• The price per share for the 6,013.35 RSUs was $13.39, based on the 20-day moving average price of the Issuer's common stock as of June 6, 2025.
• Both batches of restricted stock units (totaling 17,181 RSUs) are cash-settled and will become payable in cash upon or following the reporting person's termination of service as a director of the Issuer pursuant to the terms of the Plan.
• Following these transactions, Director Xian Ming beneficially owns 32,142.918 Restricted Stock Units directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the acquisition of equity-based compensation by a director aligns their interests with shareholders, which is generally viewed favorably. However, it is a routine compensation event rather than a direct investment decision.

Positives

• The acquisition of restricted stock units by a director aligns their interests with those of the shareholders, as their compensation is tied to the company's future performance.
• The use of a deferred compensation plan and share incentive plan indicates structured and established corporate governance practices for director remuneration.

Future Outlook

The acquired restricted stock units are set to vest on June 25, 2026, and will become payable in cash upon or following the reporting person's termination of service as a director.

Industry Context

This filing is a routine disclosure of insider compensation and does not directly reflect broader industry trends or competitive dynamics. It indicates standard practice for director remuneration within a publicly traded company.

Corporate Governance

Related Party Transactions

• The acquisition of restricted stock units by Director Xian Ming from MEDIFAST, Inc. constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders.
• Director: Receives equity-based compensation, which vests over time and is payable upon termination of service, providing a deferred benefit.

Next Steps

• Vesting of 11,167.65 Restricted Stock Units on June 25, 2026.
• Payment of cash-settled Restricted Stock Units upon or following the director's termination of service.

Key Dates

Keywords

MEDIFAST, MED, SEC Form 4, Insider Transaction, Restricted Stock Units, Director Compensation, Beneficial Ownership, Xian Ming, Corporate Governance